Your support helps us to tell the story Read more Support Now From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging. At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story. The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it. Your support makes all the difference. Read more

A simple outpatient procedure may provide a majority of people who discontinue popular weight-loss drugs a way to prevent regaining their lost pounds, scientists reveal in a new study.

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have ushered in a new era of diabetes management and weight loss, with some estimates suggesting 1 in 8 Americans could be taking these jabs.

These numbers are expected to rise as some of these drugs are starting to also become available in a pill form.

While initially developed for blood sugar control to manage diabetes, they have since become available extensively for those seeking to shed some pounds, helping patients lose anywhere from 15 per cent to 20 per cent of their body weight.

But recent studies suggest that many patients who discontinue these drugs after achieving their weight loss results are regaining nearly two-thirds of their lost pounds.

Now, a new world-first clinical trial reveals a safe, effective, and long-lasting way to maintain drug-free weight loss after GLP-1 discontinuation, scientists say.

"As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term," said Dr Shelby Sullivan from the Dartmouth Geisel School of Medicine.

“But, if they stop these medications, weight regain occurs in the vast majority of patients, and the metabolic benefits are lost,” Dr Sullivan explained.

Medicine distributor displays Mounjaro (tirzepatide) self-injecting GLP-1 prefilled pens ( AFP via Getty Images )

The new minimally invasive endoscopic procedure, known as duodenal mucosal resurfacing, may provide “lasting weight-loss maintenance”, according to scientists.

It uses targeted heat to burn the unhealthy inner mucosal lining of the duodenum, the upper part of the small intestine just below the stomach.

In the ongoing trial, scientists have been testing whether the procedure can stimulate the growth of new, healthy tissue and result in a sustained metabolic reset.

Tissues targeted by the drug are typically involved in producing hormones that are mimicked by GLP-1 drugs.

Normally, high-fat diets can lead to thickening and other changes in this tissue layer and rewire how the gut responds to food.

By rejuvenating the tissue layer, the procedure appears to reset individuals' metabolism to their new post-GLP-1 weight, scientists say.

Results from the first group of trial participants are being presented this week at Digestive Disease Week (DDW) 2026.

The study included six months of follow-up data and points to durable weight maintenance with the procedure.

Of the 45 participants included in the research, 29 underwent the endoscopic procedure, while 16 received a sham treatment.

All of the participants lost at least 15 per cent of their total weight with the GLP-1 drug tirzepatide before discontinuing the drug.

Scientists found that six months after stopping the drug, those who had the sham procedure regained 40 per cent more weight than the treatment group.

In comparison, those who underwent the procedure regained just seven pounds, maintaining over 80 per cent of their weight loss.

The weight difference between the groups also appears to be widening from one to six months post-intervention, scientists say.

"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," Dr Sullivan said, adding that the results give confidence “that we're targeting the right biology”.

"You can be back to your daily routine in about a day. Participants could not tell if they had the sham or real procedure because there are not a lot of symptoms after the procedure,” he said.